Most Read Articles
Tristan Manalac, 14 May 2020
Liver injuries appear to be more common in severe cases of coronavirus disease 2019 (COVID-19), a new meta-analysis reports.
19 May 2020
Upper respiratory (UR) and atypical symptoms are more likely to occur in children with symptomatic pharyngitis and group A Streptococcus (GAS) on throat culture identified as carrier than those who are acutely infected, according to a study.
16 May 2020
There appears to be no evidence of the SARS-CoV-2 virus in the semen of patients recovering from COVID-19 a month after diagnosis, according to a study, suggesting that the virus is unlikely to gain entry into testicular cells through an ACE2/TMPRSS2-mediated mechanism.
Stephen Padilla, 19 May 2020
Influenza A and B infections show comparable clinical severity in children, a study has shown.

Sofosbuvir-velpatasvir combo safe, effective for HCV patients with end-stage renal disease

05 Oct 2019

The combination of sofosbuvir and velpatasvir is safe and effective for the treatment of hepatitis C virus (HCV) in patients with end-stage renal disease (ESRD) undergoing haemodialysis, a study has shown.

Fifty-nine HCV patients (mean age, 60 years; 59 percent male) undergoing haemodialysis or peritoneal dialysis of ESRD were given open-label sofosbuvir/velpatasvir (400 mg/100 mg) once daily for 12 weeks. The primary efficacy endpoint was the proportion of participants reaching sustained virological response 12 weeks after the treatment was discontinued (SVR12). Discontinuation due to adverse events was the primary safety endpoint.

Almost all patients achieved SVR12 (95 percent; n=56). Most of the patients who achieved the primary efficacy endpoint had drug adherence rates of at least 90 percent. Those who fell short of SVR12 had adherence rates of <90 percent; one patient died of suicide after achieving viral suppression 79 days after treatment.

Adverse events were also fairly common, with 80 percent of the study population reporting at least one episode. Most were mild or moderate in severity.

The most common side effects were headache (17 percent), fatigue (14 percent), nausea (14 percent), vomiting (14 percent) and insomnia (10 percent). Eleven patients (19 percent) experienced serious adverse events, though none were deemed to be related to the study treatment. There were no discontinuations due to adverse events.

Aside from the suicide, one other death occurred due to metastatic lung cancer 111 days after completing the study.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Tristan Manalac, 14 May 2020
Liver injuries appear to be more common in severe cases of coronavirus disease 2019 (COVID-19), a new meta-analysis reports.
19 May 2020
Upper respiratory (UR) and atypical symptoms are more likely to occur in children with symptomatic pharyngitis and group A Streptococcus (GAS) on throat culture identified as carrier than those who are acutely infected, according to a study.
16 May 2020
There appears to be no evidence of the SARS-CoV-2 virus in the semen of patients recovering from COVID-19 a month after diagnosis, according to a study, suggesting that the virus is unlikely to gain entry into testicular cells through an ACE2/TMPRSS2-mediated mechanism.
Stephen Padilla, 19 May 2020
Influenza A and B infections show comparable clinical severity in children, a study has shown.